Zyngenia is developing a new class of biotherapeutics that better address the complexity of diseases by the simultaneous targeting of multiple physiologic pathways. These highly specific, single molecule drugs are able to more effectively treat multi-factorial diseases such as cancer, inflammation and autoimmune disorders.
The Company's pipeline is comprised of monoclonal antibody (mAb)-based drugs that are able to concomitantly engage several validated disease targets through the genetic fusion of additional peptide binding motifs to the mAb. Zyngenia has advanced three programs into preclinical development and achieved preclinical proof-of-concept with both bi-specific and tri-specific programs in cancer and inflammation.
The Company's game-changing technology surpasses other biological platforms in creating innovative and differentiated mAb-based therapeutics (called Zybodies™) that combine multi-functionality with the drug-like properties of conventional mAbs, all while using standard commercial production processes. This technology platform and the resulting programs generate multiple opportunities for discovery and licensing partnerships to address a broad spectrum of diseases.
Zyngenia was founded by Carlos Barbas of the Scripps Research Institute, and initiated operations in 2009 with $25M in funding from New Enterprise Associates. Since that time, the Company has assembled a top management team and a team of scientific and clinical advisors and has expanded its intellectual property portfolio to protect its technology and programs.